elotuzumab (Empliciti)
elotuzumab is an FDA-licensed reference biologic from Bristol-Myers Squibb Company. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2015
Reference approved
Reference product
Empliciti elotuzumab
Bristol-Myers Squibb Company
- Approved
- Nov 30, 2015
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for elotuzumab, in chronological order.
Reference approval
Approval date of the reference elotuzumab product.
10 yr 8 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
7 mo ago
Frequently asked questions
Are there biosimilars approved for elotuzumab (Empliciti)?
No 351(k) biosimilars or interchangeable biosimilars referencing elotuzumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.